Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Ascendis Pharma A (ASND) over the last 14 years, with Q3 2025 value amounting to $630.2 million.

  • Ascendis Pharma A's Cash & Current Investments fell 825.74% to $630.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $630.2 million, marking a year-over-year decrease of 825.74%. This contributed to the annual value of $605.6 million for FY2024, which is 4091.52% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Cash & Current Investments of $630.2 million as of Q3 2025, which was down 825.74% from $559.2 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Cash & Current Investments ranged from a high of $849.4 million in Q1 2022 and a low of $278.6 million during Q2 2024
  • Moreover, its 5-year median value for Cash & Current Investments was $544.8 million (2025), whereas its average is $556.6 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 4035.83% in 2023, then surged by 10074.2% in 2025.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Cash & Current Investments stood at $515.7 million in 2021, then decreased by 8.65% to $471.1 million in 2022, then decreased by 8.77% to $429.8 million in 2023, then soared by 39.13% to $597.9 million in 2024, then rose by 5.4% to $630.2 million in 2025.
  • Its Cash & Current Investments stands at $630.2 million for Q3 2025, versus $559.2 million for Q2 2025 and $544.8 million for Q1 2025.